These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 18410600)

  • 1. Antiviral therapy for various stages of HBV-related diseases: lamivudine and beyond.
    Jia JD
    J Gastroenterol Hepatol; 2008 May; 23(5):681-2. PubMed ID: 18410600
    [No Abstract]   [Full Text] [Related]  

  • 2. Role of long-term lamivudine treatment of hepatitis B virus recurrence after liver transplantation.
    Woo HY; Choi JY; Jang JW; You CR; Bae SH; Yoon SK; Yang JM; Choi SW; Han NI; Kim DG
    J Med Virol; 2008 Nov; 80(11):1891-9. PubMed ID: 18814257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China.
    Yao GB; Zhu M; Cui ZY; Wang BE; Yao JL; Zeng MD
    J Dig Dis; 2009 May; 10(2):131-7. PubMed ID: 19426396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy.
    Shouval D; Lai CL; Chang TT; Cheinquer H; Martin P; Carosi G; Han S; Kaymakoglu S; Tamez R; Yang J; Tenney D; Brett-Smith H
    J Hepatol; 2009 Feb; 50(2):289-95. PubMed ID: 19070393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multidrug resistance after lamivudine therapy for chronic hepatitis B.
    Sarrecchia C; Volpi A; Sordillo P; Andreoni M
    Int J Infect Dis; 2009 May; 13(3):e133-4. PubMed ID: 18990599
    [No Abstract]   [Full Text] [Related]  

  • 6. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment.
    Liaw YF
    Liver Int; 2009 Jan; 29 Suppl 1():100-7. PubMed ID: 19207972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The efficacy of lamivudine in Korean patients with chronic hepatitis B].
    Choi JY
    Korean J Hepatol; 2005 Mar; 11(1):25-30. PubMed ID: 15788881
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy.
    Pessôa MG; Gazzard B; Huang AK; Brandão-Mello CE; Cassetti I; Mendes-Corrêa MC; Soriano V; Phiri P; Hall A; Brett-Smith H
    AIDS; 2008 Sep; 22(14):1779-87. PubMed ID: 18753861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Withdrawal of lamivudine in HBeAg-positive chronic hepatitis B patients after achieving effective maintained virological suppression.
    Yeh CT; Hsu CW; Chen YC; Liaw YF
    J Clin Virol; 2009 Jun; 45(2):114-8. PubMed ID: 19451024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is entecavir ideal for the treatment of lamivudine-refractory chronic hepatitis B?
    Su CW; Wu JC; Lee SD
    Hepatology; 2008 Nov; 48(5):1726-7; author reply 1727-8. PubMed ID: 18972445
    [No Abstract]   [Full Text] [Related]  

  • 11. Screening for and treating hepatitis B virus in patients with HIV infection.
    Tillmann HL
    Clin Infect Dis; 2007 Sep; 45(5):633-6. PubMed ID: 17683000
    [No Abstract]   [Full Text] [Related]  

  • 12. Selection of precore mutants during lamivudine treatment in patients with chronic hepatitis B.
    Cheong JY; Cho SW; Yoo JH; Hong SP; Kim SO; Yoo WD; Kim JH
    Hepatogastroenterology; 2008; 55(84):1029-33. PubMed ID: 18705323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction value of model for end-stage liver disease scoring system on prognosis in patients with acute-on-chronic hepatitis B liver failure after plasma exchange and lamivudine treatment.
    Yu JW; Sun LJ; Zhao YH; Li SC
    J Gastroenterol Hepatol; 2008 Aug; 23(8 Pt 1):1242-9. PubMed ID: 18637053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic cirrhotic hepatitis B patients with a high incidence of hepatic decompensation after viral breakthrough with lamivudine-resistant mutants and during rescue treatment.
    Joo MK; Yeon JE; Kim JH; Jung YK; Lee SJ; Kim JH; Yim HJ; Byun KS; Park JJ; Kim JS; Bak YT
    Scand J Gastroenterol; 2008; 43(12):1514-21. PubMed ID: 18663665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Lamivudine treatment of a HBs antigen positive man with reactive arthritis].
    Borup C; Siboni A
    Ugeskr Laeger; 2008 Nov; 170(48):3940-1. PubMed ID: 19087731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Annular leukocytoclastic vasculitis in association with chronic hepatitis B.
    Meissner M; Beier C; Gille J; Kaufmann R
    J Eur Acad Dermatol Venereol; 2007 Jan; 21(1):135-6. PubMed ID: 17207198
    [No Abstract]   [Full Text] [Related]  

  • 17. Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B.
    Wong VW; Wong GL; Tsang SW; Hui AY; Chim AM; Yiu KK; Chan HY; Chan FK; Sung JJ; Chan HL
    Antivir Ther; 2008; 13(4):571-9. PubMed ID: 18672536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of chronic hepatitis B virus infection - Dutch national guidelines.
    Buster EH; van Erpecum KJ; Schalm SW; Zaaijer HL; Brouwer JT; Gelderblom HC; de Knegt RJ; Minke Bakker C; Reesink HW; Janssen HL;
    Neth J Med; 2008; 66(7):292-306. PubMed ID: 18663260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy of antiviral treatment on intrahepatic HBV DNA and histology in HBeAg -positive chronic hepatitis B patients].
    Lu HY; Zhuang LW; Yu YY; Si CW; Zheng JJ; Chen XY; Han ZH; Chen Y
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2008 Feb; 22(1):54-6. PubMed ID: 18414702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of lamivudine-induced HBsAg loss rate according to age in children with chronic hepatitis B].
    Kim JM; Choe BH; Chu MA; Cho SM
    Korean J Hepatol; 2009 Jun; 15(2):168-78. PubMed ID: 19581769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.